Tags

Type your tag names separated by a space and hit enter

Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Int J Oncol. 2000 Oct; 17(4):673-81.IJ

Abstract

Matrix metalloproteinases (MMPs) are known to play an important role in cancer cell invasion by mediating the degradation of extracellular matrix proteins. The activity of such MMPs are regulated by tissue inhibitors of metalloproteinases (TIMPs). In this study, we investigated the immunohistochemical expression of MMP-2, MT1-MMP, TIMP-2, MMP-9, and TIMP-1 in 114 epithelial ovarian tumors (14 adenomas, 22 borderline tumors, and 78 adenocarcinomas). mRNA expression of MMP-2, MT1-MMP, and TIMP-2 was determined by RT-PCR in selected samples. The diffuse positive rates of MMP-2, MT1-MMP, TIMP-2, and MMP-9 in ovarian carcinomas were significantly higher than those in the borderline and in benign tumors. Conversely, the diffuse positive rate of TIMP-1 was higher in the benign and borderline ovarian tumors than that in ovarian carcinomas. The percentages of the cases with triple diffuse positive expression for MMP-2, MT1-MMP, and TIMP-2 within the same tumor was significantly higher in malignant tumors than those in borderline and in benign tumors. With respect to clinical stage, the triple diffuse positive rate in advanced-stage (stage II/III/IV) carcinomas was significantly higher than that in early-stage (stage I) carcinomas. A significantly higher triple diffuse positive rate was also observed in high-grade (grade 2/3) disease than in low-grade (grade 1) disease. Considerable levels of mRNA expression of MMP-2, MT1-MMP and TIMP-2 were detected in all selected samples that showed triple diffuse positive immunostaining, confirming the co-expression of MMP-2, MT1-MMP, and TIMP-2 at the transcriptional level within the same tumor. All cases with diffuse positive expression for MMP-9 showed regional or negative TIMP-1 expression. The diffuse positive rate of MMP-9 was significantly higher in ovarian carcinomas with lymph node metastasis than in those without lymph node metastasis. Our results suggest that the overexpression of MMP-2, MT1-MMP, TIMP-2, and MMP-9 and down-regulation of TIMP-1 may contribute to the development or enhanced growth capacity of ovarian tumors. Co-expression of MMP-2, MT1-MMP, and TIMP-2 within the same tumor seems to play an important role in the progression of ovarian cancer. Elevated MMP-9 expression together with low expression of TIMP-1 may also contribute to the lymph node metastasis of ovarian carcinoma cells.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Sakata K
Department of Obstetrics and Gynecology, Hiroshima University School of Medicine, Minami-ku, Hiroshima 734-8551, Japan.
Shigemasa K
No affiliation info available
Nagai N
No affiliation info available
Ohama K
No affiliation info available

MeSH

FemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix MetalloproteinasesMatrix Metalloproteinases, Membrane-AssociatedMetalloendopeptidasesNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsRNA, MessengerTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinases

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10995877

Citation

Sakata, K, et al. "Expression of Matrix Metalloproteinases (MMP-2, MMP-9, MT1-MMP) and Their Inhibitors (TIMP-1, TIMP-2) in Common Epithelial Tumors of the Ovary." International Journal of Oncology, vol. 17, no. 4, 2000, pp. 673-81.
Sakata K, Shigemasa K, Nagai N, et al. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000;17(4):673-81.
Sakata, K., Shigemasa, K., Nagai, N., & Ohama, K. (2000). Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. International Journal of Oncology, 17(4), 673-81.
Sakata K, et al. Expression of Matrix Metalloproteinases (MMP-2, MMP-9, MT1-MMP) and Their Inhibitors (TIMP-1, TIMP-2) in Common Epithelial Tumors of the Ovary. Int J Oncol. 2000;17(4):673-81. PubMed PMID: 10995877.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. AU - Sakata,K, AU - Shigemasa,K, AU - Nagai,N, AU - Ohama,K, PY - 2000/9/21/pubmed PY - 2001/2/28/medline PY - 2000/9/21/entrez SP - 673 EP - 81 JF - International journal of oncology JO - Int J Oncol VL - 17 IS - 4 N2 - Matrix metalloproteinases (MMPs) are known to play an important role in cancer cell invasion by mediating the degradation of extracellular matrix proteins. The activity of such MMPs are regulated by tissue inhibitors of metalloproteinases (TIMPs). In this study, we investigated the immunohistochemical expression of MMP-2, MT1-MMP, TIMP-2, MMP-9, and TIMP-1 in 114 epithelial ovarian tumors (14 adenomas, 22 borderline tumors, and 78 adenocarcinomas). mRNA expression of MMP-2, MT1-MMP, and TIMP-2 was determined by RT-PCR in selected samples. The diffuse positive rates of MMP-2, MT1-MMP, TIMP-2, and MMP-9 in ovarian carcinomas were significantly higher than those in the borderline and in benign tumors. Conversely, the diffuse positive rate of TIMP-1 was higher in the benign and borderline ovarian tumors than that in ovarian carcinomas. The percentages of the cases with triple diffuse positive expression for MMP-2, MT1-MMP, and TIMP-2 within the same tumor was significantly higher in malignant tumors than those in borderline and in benign tumors. With respect to clinical stage, the triple diffuse positive rate in advanced-stage (stage II/III/IV) carcinomas was significantly higher than that in early-stage (stage I) carcinomas. A significantly higher triple diffuse positive rate was also observed in high-grade (grade 2/3) disease than in low-grade (grade 1) disease. Considerable levels of mRNA expression of MMP-2, MT1-MMP and TIMP-2 were detected in all selected samples that showed triple diffuse positive immunostaining, confirming the co-expression of MMP-2, MT1-MMP, and TIMP-2 at the transcriptional level within the same tumor. All cases with diffuse positive expression for MMP-9 showed regional or negative TIMP-1 expression. The diffuse positive rate of MMP-9 was significantly higher in ovarian carcinomas with lymph node metastasis than in those without lymph node metastasis. Our results suggest that the overexpression of MMP-2, MT1-MMP, TIMP-2, and MMP-9 and down-regulation of TIMP-1 may contribute to the development or enhanced growth capacity of ovarian tumors. Co-expression of MMP-2, MT1-MMP, and TIMP-2 within the same tumor seems to play an important role in the progression of ovarian cancer. Elevated MMP-9 expression together with low expression of TIMP-1 may also contribute to the lymph node metastasis of ovarian carcinoma cells. SN - 1019-6439 UR - https://www.unboundmedicine.com/medline/citation/10995877/Expression_of_matrix_metalloproteinases__MMP_2_MMP_9_MT1_MMP__and_their_inhibitors__TIMP_1_TIMP_2__in_common_epithelial_tumors_of_the_ovary_ L2 - https://www.spandidos-publications.com/ijo/17/4/673 DB - PRIME DP - Unbound Medicine ER -